Invivyd, Inc. (NASDAQ:IVVD) Short Interest Up 5.2% in January

Invivyd, Inc. (NASDAQ:IVVD) was the recipient of a large growth in short interest in the month of January. As of January 31st, there was short interest totalling 6,620,000 shares, a growth of 5.2% from the January 15th total of 6,290,000 shares. Based on an average daily trading volume, of 12,710,000 shares, the days-to-cover ratio is presently 0.5 days. Approximately 8.8% of the company’s shares are sold short.

Invivyd Stock Performance

NASDAQ:IVVD opened at $1.46 on Wednesday. The stock has a 50-day simple moving average of $0.73 and a 200-day simple moving average of $0.86. The stock has a market cap of $174.65 million, a P/E ratio of -0.74 and a beta of 0.61. Invivyd has a 1 year low of $0.35 and a 1 year high of $4.74.

Insider Activity at Invivyd

In related news, Director Terrance Mcguire sold 160,400 shares of the business’s stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $0.59, for a total value of $94,636.00. Following the sale, the director now owns 4,202,679 shares in the company, valued at approximately $2,479,580.61. The trade was a 3.68 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last 90 days, insiders have sold 816,466 shares of company stock worth $423,214. 17.90% of the stock is currently owned by company insiders.

Institutional Trading of Invivyd

A number of large investors have recently made changes to their positions in the company. Mithril II GP LP acquired a new stake in shares of Invivyd in the 4th quarter valued at about $4,981,000. State Street Corp boosted its position in shares of Invivyd by 3.7% in the 3rd quarter. State Street Corp now owns 1,018,640 shares of the company’s stock valued at $1,039,000 after purchasing an additional 35,904 shares during the period. Deutsche Bank AG boosted its position in shares of Invivyd by 35.2% in the 4th quarter. Deutsche Bank AG now owns 874,406 shares of the company’s stock valued at $385,000 after purchasing an additional 227,463 shares during the period. Two Sigma Investments LP boosted its position in shares of Invivyd by 125.3% in the 4th quarter. Two Sigma Investments LP now owns 367,100 shares of the company’s stock valued at $163,000 after purchasing an additional 204,188 shares during the period. Finally, Two Sigma Advisers LP boosted its position in shares of Invivyd by 1,276.5% in the 4th quarter. Two Sigma Advisers LP now owns 304,200 shares of the company’s stock valued at $135,000 after purchasing an additional 282,100 shares during the period. 70.36% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Invivyd in a report on Tuesday, February 4th. EF Hutton Acquisition Co. I upgraded Invivyd to a “strong-buy” rating in a report on Wednesday, October 30th. D. Boral Capital restated a “buy” rating and set a $9.00 price target on shares of Invivyd in a report on Monday, February 3rd. Finally, Morgan Stanley cut their price target on Invivyd from $9.50 to $3.55 and set an “overweight” rating on the stock in a report on Wednesday, November 20th. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Invivyd has an average rating of “Buy” and an average price target of $7.89.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.